Pamorelin

Locally advanced or metastatic, hormone-dependent prostate cancer. Concomitant to & following RT in patients w/ high-risk localized or locally advanced prostate cancer. 3.75 mg: Endometriosis. Pituitary down-regulation in the context of assisted reproduction technology. Adjuvant treatment, in combination w/ tamoxifen or an aromatase inhibitor (AI), hormone receptor +ve early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. 22.5 mg: Central precocious puberty (CPP) in childn ≥2 yr w/ onset of CPP before 8 yr in girls & 10 yr in boys.

IM 3.75 mg 1 inj every 4 wk. 11.25 mg 1 inj every 12 wk. 22.5 mg 1 inj every 24 wk. Pituitary down-regulation in the context of medically assisted procreation (IVF, GIFT, etc) 3.75 mg either on the 2nd day of menstrual cycle or 21st day of previous cycle. Breast cancer 3.75 mg every 4 wk in combination w/ tamoxifen or AI. Initiate 3.75 mg inj at least 6-8 wk before staring AI treatment; administer min of 2 inj of Pamorelin 3.75 mg (w/ a 4-wk interval between inj) before AI treatment commencement.

Hypersensitivity to triptorelin, gonadotropin-releasing hormone (GnRH) or other GnRH agonist analogues. Patients w/ spinal cord compression secondary to prostate cancer metastases; unexplained vag bleeding. AI initiation before adequate ovarian suppression w/ triptorelin has been achieved. Pregnancy & lactation.

Cancer Hormone Therapy

L02AE04 - triptorelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.

POM